Chongqing Pharscin Pharmaceutical (SHE:002907) obtained re-registration approval from the Chongqing drug administrator for its omeprazole sodium injection.
The proton pump inhibitor treats conditions such as peptic ulcer bleeding and reflux esophagitis, according to a Wednesday filing with the Shenzhen bourse.
The approval is valid until January 2031.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments